BRIEF: Kelun-Biotech raises $250 million through share placement
Innovative cancer drug company Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. (6990.HK) announced on Thursday it plans to sell 5.92 million shares through a placement, representing 2.54% of its enlarged share capital.…
No respite for RemeGen as problems and losses pile up
The developer of innovative drugs has sustained a series of blows to its finances, corporate partnerships, management team and star product, leaving investors jittery Key Takeaways: Despite rising revenue, RemeGen…
Kelun-Biotech hopes for IPO booster from new Merck partnership
The company welcomed Merck as new shareholder not long after the pair signed a lucrative licensing agreement for its cutting-edge ADC cancer treatment Key Takeaways: Despite a lack of products…
